Abstract
Background HIV testing services (HTS) aim to increase HIV status awareness and serve as the gateway to prevention, care, and treatment. Understanding clients’ experiences accessing facility-based HTS is important to ensure comprehensive service provision, improve linkage to care, and ultimately contribute to better health outcomes.
Methods We surveyed a convenience sample of adults presenting for HIV testing at 42 health facilities in Malawi, South Africa, and Zambia between September 2022 and April 2023. A structured questionnaire captured data on HTS history, reasons for testing, services obtained, and offer and uptake of pre-exposure prophylaxis (PrEP) or treatment. Open-ended questions captured participants’ experiences qualitatively. We report participant characteristics, experiences, and services provided using proportions stratified by country and HIV test result and summarize emergent themes from qualitative responses.
Results We enrolled 1,142 clients who presented for facility-based HIV testing (324 from Malawi, 389 from South Africa, 429 from Zambia). Of these, 32%, 24%, and 34% tested positive for HIV in Malawi, South Africa, and Zambia, respectively. Although most participants had tested for HIV prior to the current test, this proportion varied by country and current test result but was substantially lower for positive testers (64%, 66%, and 71% for Malawi, South Africa and Zambia) than for negative testers (82%, 88%, and 86%, respectively). Over a third of those who tested positive for HIV at this test had never previously tested for HIV. Among participants who tested positive, ill health was most frequently reported as the reason for testing; negative testers most often reported testing voluntarily (for their own information). Most participants reported being tested by lay counselors and receiving counseling before and after testing. Most participants who tested positive reported receiving ART initiation services, but fewer than a third in Malawi and South Africa and 39% in Zambia said they received adherence counselling. The proportion of those testing negative who were offered PrEP varied across the three countries, ranging from 27% of females in Malawi to 53% of females in Zambia. Participants in all three countries reported high satisfaction with the HTS services received and many qualitatively described high quality counseling, feelings of encouragement, and kind, warm treatment by providers.
Conclusion While HIV testing clients in Malawi, South Africa, and Zambia were generally satisfied with their testing experiences, we identified opportunities for improvement in HTS services. ART adherence counseling was not universally provided, and prevention services were not offered to most negative testers. Of concern are the large proportion of positive testers who had never been tested before and self-reported testing because of ill health, which may indicate late presentation for testing. Emphasis on comprehensive linkage to services should be prioritized for all clients presenting for HIV testing.
Statements and Declarations We have no financial or non-financial competing interests to disclose.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT05886530
Funding Statement
Funding for the study was provided by the Bill & Melinda Gates Foundation through OPP1192640 to Boston University and INV-037138 to the Wits Health Consortium.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval to conduct this study was granted by University of Witwatersrand (Medical) Human Research Ethics Committee in South Africa (Protocol M210241), the National Health Science Research Committee (NHSRC) in Malawi (protocol 21/03/2672), ERES Converge Institutional Review Board in Zambia (Protocol 2021-Mar-012), and by the Boston University Medical Campus Institutional Review Board in the United States (Protocol H-41402).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.